You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

osimertinib

Showing 1 - 25 of 272
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 Trial in

Not yet recruiting
  • Metastatic Lung Non-Small Cell Carcinoma
  • +2 more
  • Cetuximab
  • +2 more
  • Sacramento, California
    University of California Davis Comprehensive Cancer Center
Oct 2, 2023

NSCLC With Mutation in Epidermal Growth Factor Receptor Trial (Osimertinib, Aspirin)

Not yet recruiting
  • Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
  • (no location specified)
Aug 27, 2023

NSCLC Trial in Singapore (Oral S-1 + Oral Osimertinib)

Not yet recruiting
  • NSCLC
  • Oral S-1 + Oral Osimertinib
  • Singapore, Singapore
    National Cancer Center Singapore
Mar 6, 2023

Stage IV NSCLC Trial in Wuhan (SBRT+Osimertinib, Osimertinib 80 MG)

Not yet recruiting
  • Stage IV Non-small Cell Lung Cancer
  • SBRT+Osimertinib
  • Osimertinib 80 MG
  • Wuhan, Hubei, China
    Tongji Hospital Affiliated to Tongji Medical College of Huazhong
Oct 13, 2022

NSCLC Trial (Cobicistat)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • (no location specified)
Feb 17, 2023

OSIREAL - Osimertinib RWE on EGFRm NSCLC in Spain

Recruiting
  • Non-small Cell Lung Cancer
    • Santiago de Compostela, Galicia, Spain
      Luis Ángel Leon Mateos
    Oct 3, 2023

    NSCLC Trial in Santa Rosa, Ridgewood (Tipifarnib, Osimertinib)

    Recruiting
    • NSCLC
    • Santa Rosa, California
    • +1 more
    Jan 11, 2023

    NSCLC Trial in China (BBP-398, osimertinib)

    Recruiting
    • NSCLC
    • Beijing, Beijing, China
    • +4 more
    Sep 4, 2023

    Colorectal Cancer, NSCLC Trial (GDC-1971, Osimertinib, Cetuximab)

    Not yet recruiting
    • Colorectal Cancer
    • Non-Small Cell Lung Cancer
    • (no location specified)
    Jul 12, 2023

    NSCLC, Stage I Trial in Tianjin (Osimertinib)

    Recruiting
    • NSCLC, Stage I
    • Osimertinib
    • Tianjin, Tianjin, China
      Tianjin Medical University Cancer Institute & Hospital
    Jan 6, 2023

    NSCLC Trial in Shanghai (BL-B01D1, Osimertinib Mesylate Tablets)

    Not yet recruiting
    • Non-small Cell Lung Cancer
    • Shanghai, Shanghai, China
      Shanghai Pulmonary Hospital
    May 25, 2023

    Cancer Trial (Osimertinib)

    Not yet recruiting
    • Cancer
    • Osimertinib
    • (no location specified)
    Nov 17, 2022

    NSCLC (NSCLC) Trial (Osimertinib, Amivantamab)

    Not yet recruiting
    • Non-Small Cell Lung Cancer (NSCLC)
    • (no location specified)
    Mar 24, 2023

    Double-dose Furmonertinib in Treatment of Slow

    Not yet recruiting
    • Non Small Cell Lung Cancer
    • +3 more
    • (no location specified)
    Oct 31, 2023

    NSCLC Trial (Telisotuzumab Vedotin, Osimertinib, Cisplatin)

    Not yet recruiting
    • Non-Small Cell Lung Cancer
    • Telisotuzumab Vedotin
    • +4 more
    • (no location specified)
    Oct 17, 2023

    LMV-12 Combined With Osimertinib in NSCLC

    Not yet recruiting
    • Non Small Cell Lung Cancer
    • LMV-12(HE003) and Osimertinib
    • Changsha, Hunan, China
      Hunan Cancer Hospital
    Oct 25, 2023

    Lung Adenocarcinoma, Lung Tumors Trial run by the NCI (osimertinib, LAT)

    Completed
    • Lung Adenocarcinoma
    • Lung Neoplasms
    • osimertinib
    • LAT
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Oct 17, 2022

    Non Small Cell Lung Cancer, Lung Cancer Trial in Los Angeles (Osimertinib, Carotuximab)

    Recruiting
    • Non Small Cell Lung Cancer
    • Lung Cancer
    • Los Angeles, California
      Cedars-Sinai Medical Center
    Dec 20, 2022

    A Multicountry, Multicentre, Non-interventional, Retrospective

    Recruiting
    • Carcinoma, Non-Small-Cell Lung
      • Kuwait, Kuwait
        Kuwait Cancer Control Center
      Sep 13, 2023

      Lung Cancer Metastatic, EGFR Gene Mutation Trial in San Francisco (Osimertinib, Alisertib)

      Recruiting
      • Lung Cancer Metastatic
      • EGFR Gene Mutation
      • San Francisco, California
        University of California, San Francisco
      Aug 10, 2022

      Non Small Cell Lung Cancer Trial in Italy (Osimertinib)

      Recruiting
      • Non Small Cell Lung Cancer
      • Osimertinib
      • Ancona, Italy
      • +10 more
      Mar 14, 2023

      NSCLC Trial in Boston (Osimertinib)

      Recruiting
      • Carcinoma, Non-Small-Cell Lung
      • Osimertinib
      • Boston, Massachusetts
      • +1 more
      Sep 28, 2022

      Recurrent Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8 Trial in Houston

      Active, not recruiting
      • Recurrent Lung Non-Small Cell Carcinoma
      • +4 more
      • Houston, Texas
        M D Anderson Cancer Center
      Jul 31, 2022

      NSCLC (NSCLC) Trial in Japan, United States (Patritumab deruxtecan, Osimertinib)

      Recruiting
      • Non-Small Cell Lung Cancer (NSCLC)
      • Patritumab deruxtecan
      • Osimertinib
      • Santa Monica, California
      • +13 more
      Feb 1, 2023

      NSCLC, EGFR Activating Mutation Trial in Changsha, Shanghai (TY-9591, Osimertinib, Osimertinib)

      Recruiting
      • NSCLC
      • EGFR Activating Mutation
      • Changsha, Hunan, China
      • +1 more
      Dec 6, 2022